About Element Genomics
Element Genomics is a Healthcare company based in Durham (United States) founded in 2015, and was acquired by UCB in April 2018. An epigenomic editing platform is developed to identify drug targets. Element Genomics has raised $4.85 million across 1 funding round from investors including UCB. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its legal entity is Element Genomics, Inc. Its competitors include Beam Therapeutics, eGenesis and Korro Bio; 3 of its 3 listed competitors have raised funding.
Company details
Element Genomics was founded in 2015 in Durham, United States, within the biotechnology sector. An epigenomic editing platform is developed in collaboration with Duke University to characterize the non-coding genome and map gene function and regulation. Operations center on identifying new drug targets, with emphasis placed on neurology and immunology therapeutic areas. The companys domain is elementgenomics.com.
- Headquarters Durham, United States
- Stage Acquired
- SectorsHealthcare
- Website elementgenomics.com
- Acquired by UCB (Apr 2018)
- Legal Name Element Genomics, Inc.
Funding Insights of Element Genomics
Element Genomics has successfully raised a total of $4.85M through 1 strategic funding round. The most recent funding activity was a Series A round of $4.85 million completed in November 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.85M
- Total Rounds 1
- Last Round Series A — $4.85M
- First Round $4.85M
(Nov 2016)
All 1 funding rounds of Element Genomics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2016 | $4.85M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in Element Genomics
Element Genomics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include UCB.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Therapies for immunological and neurological disorders are developed. | 1928 | ucb.com | Brussels, Belgium |
Investor details for Element Genomics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Element Genomics
3 dated milestones of Element Genomics across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Element Genomics is founded.
- Funding First funding round of $4.8M.
- Exit Acquired by UCB.
Competitors of Element Genomics
Element Genomics has 3 listed competitors in our database, 3 of them funded. They include Beam Therapeutics, eGenesis and Korro Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| beamtx.com | 2017 | Cambridge, United States | $222M | 340 | Developer of gene therapy using CRISPR base editing to treat diseases | |
| egenesisbio.com | 2015 | Cambridge, United States | $481.42M | 94 | Gene transplantation platform for humanizing pig cells is developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. |
Detailed competitors of Element Genomics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Element Genomics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Element Genomics
Element Genomics was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Element Genomics is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Element Genomics is a funded company, having raised a total of $4.85M across 1 funding round to date. The company's 1st funding round was a Series A of $4.85M, raised on Nov 2016.
Element Genomics was founded in 2015 in Durham, United States, within the biotechnology sector. An epigenomic editing platform is developed in collaboration with Duke University to characterize the non-coding genome and map gene function and regulation. Operations center on identifying new drug targets, with emphasis placed on neurology and immunology therapeutic areas. The companys domain is elementgenomics.com.
Element Genomics's top competitors include eGenesis, Korro Bio and Beam Therapeutics.
Element Genomics has 1 investor. Key investors include UCB.
Element Genomics operates through Element Genomics, Inc..
Yes. Element Genomics was acquired by UCB in April 2018.